US5998151A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for predicting the efficacy of a chemotherapeutic regimen for gastrointestinal cancers using antibodies specific for thymidylate synthase
Assignee: United States Department of Health and Human Services
•
Filing: 1996-11-27
•
Granted: 1999-12-07
•
Expires: 2016-11-27
Abstract
Abstract Methods for determining whether a chemotherapeutic treatment is appropriate for patients afflicted with gastrointestinal cancers, comprising; (a) obtaining a solid tumor tissue sample from the patient; (b) measuring a thymidylate synthase expression level in the tissue sample; and (c) comparing the thymidylate synthase expression level with a group of standard tumor tissue samples, the standards having known thymidylate synthase expression levels and known responses to the chemotherapeutic treatment, to determine if that chemotherapeutic treatment is appropriate for the patient.
Inventors
- 👤 Patrick G. Johnston
- 👤 Carmen J. Allegra
- 👤 Edwin R. Fisher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 11:25
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/10; C12N9/12; C12N9/1229; C07; C07K; C07K16/00; C07K16/40; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/573; G01N33/575; G01N33/5758; G01N2800/00; G01N2800/52
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
106 words
A method for predicting the efficacy of chemotherapeutic treatment comprising drugs that target thymidylate synthase for patients afflicted with gastrointestinal cancer, said method comprising; (a) obtaining a solid tumor tissue sample from said patient, wherein the sample is obtained prior to chemotherapeutic treatment; (b) measuring a thymidylate synthase protein level in said tissue sample; and (c) comparing said thymidylate synthase protein level with a group of standard tumor tissue samples obtained prior to chemotherapeutic treatment, said standards having known thymidylate synthase protein levels and known responses to said chemotherapeutic treatment, to predict the efficacy of chemotherapeutic treatment comprising drugs that target thymidylate synthase for said patient.
Claim 2
Independent Claim
106 words
A method for predicting the efficacy of chemotherapeutic treatment comprising drugs that target thymidylate synthase for patients afflicted with gastrointestinal cancer, said method comprising; (a) obtaining a solid tumor tissue sample from said patient, wherein the sample is obtained prior to chemotherapeutic treatment; (b) measuring a thymidylate synthase protein level in said tissue sample; and (c) comparing said thymidylate synthase protein level with a group of standard tumor tissue samples obtained prior to chemotherapeutic treatment, said standards having known thymidylate synthase protein levels and known responses to said chemotherapeutic treatment, to predict the efficacy of chemotherapeutic treatment comprising drugs that target thymidylate synthase for said patient.
Claim 3
Dependent Claim
29 words
A method in accordance with claim 1, wherein said gastrointestinal cancer is a cancer selected from the group consisting of rectal cancer, colon cancer, gastric cancer and gastroesophageal cancer.
Claim 4
Dependent Claim
14 words
A method in accordance with claim 1, wherein said gastrointestinal cancer is colon cancer.
Claim 5
Dependent Claim
14 words
A method in accordance with claim 1, wherein said gastrointestinal cancer is rectal cancer.
Claim 6
Dependent Claim
14 words
A method in accordance with claim 1, wherein said gastrointestinal cancer is gastric cancer.
Claim 7
Dependent Claim
14 words
A method in accordance with claim 1, wherein said gastrointestinal cancer is gastroesophageal cancer.
Claim 8
Dependent Claim
28 words
A method in accordance with claim 1, wherein said measuring comprises densitometry following contacting said tissue sample or a preparation thereof with an antibody specific for thymidylate synthase.
Claim 9
Dependent Claim
21 words
A method in accordance with claim 1, wherein said chemotherapeutic treatment is a neoadjuvant treatment comprising 5-fluorouracil, leucovorin and interferon α-2a.
Claim 10
Dependent Claim
21 words
A method in accordance with claim 1, wherein said chemotherapeutic treatment is an adjuvant treatment comprising 5-fluorouracil, leucovorin and interferon α-2a.
Claim 11
Dependent Claim
22 words
A method in accordance with claim 7, wherein said antibody is a TS 106 monoclonal antibody, produced by hybridoma ATCC No. HB-12497.
Claim 12
Dependent Claim
26 words
A method in accordance with claim 1, wherein measuring the thymidylate synthase protein level comprises measuring the amount of total thymidylate synthase protein in said tissue.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-12-06 | 2003-06-07 | 2003-12-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-12-06 | 2007-06-07 | 2007-12-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-12-06 | 2011-06-07 | 2011-12-07 | $7700.00 | Window Closed / Lapsed |